|
Originally published In Press as doi:10.1074/jbc.M207622200 on October 28, 2002
J. Biol. Chem., Vol. 277, Issue 52, 50842-50854, December 27, 2002
Early Mitochondrial Activation and Cytochrome c
Up-regulation during Apoptosis*,
Dhyan
Chandra ,
Jun-Wei
Liu, and
Dean G.
Tang§
From the Department of Carcinogenesis, University of Texas M. D. Anderson Cancer Center, Science Park Research Division,
Smithville, Texas 78957
Received for publication, July 29, 2002, and in revised form, October 22, 2002
 |
ABSTRACT |
Apoptosis induced by many stimuli requires the
mitochondrial respiratory chain (MRC) function. While studying the
molecular mechanisms underlying this MRC-dependent apoptotic
pathway, we find that apoptosis in multiple cell types induced by
a variety of stimuli is preceded by an early induction of MRC proteins
such as cytochrome c (which is encoded by a nuclear gene)
and cytochrome c oxidase subunit II (COX II) (which is
encoded by the mitochondrial genome). Several non-MRC proteins
localized in the mitochondria, e.g. Smac, Bim, Bak, and
Bcl-2, are also rapidly up-regulated. The up-regulation of many of
these proteins (e.g. cytochrome c, COX II, and
Bim) results from transcriptional activation of the respective genes.
The up-regulated cytosolic cytochrome c rapidly translocates to the mitochondria, resulting in an accumulation of
holocytochrome c in the mitochondria accompanied by
increasing holocytochrome c release into the cytosol. The
increased cytochrome c transport from cytosol to the
mitochondria does not depend on the mitochondrial protein synthesis or
MRC per se. In contrast, cytochrome c release
from the mitochondria involves dynamic changes in Bcl-2 family proteins
(e.g. up-regulation of Bak, Bcl-2, and Bcl-xL),
opening of permeability transition pore, and loss of mitochondrial
membrane potential. Overexpression of cytochrome c enhances
caspase activation and promotes cell death in response to apoptotic
stimulation, but simple up-regulation of cytochrome c using
an ecdysone-inducible system is, by itself, insufficient to induce
apoptosis. Taken together, these results suggest that apoptosis induced
by many stimuli involves an early mitochondrial activation, which may
be responsible for the subsequent disruption of MRC functions, loss of
 m, cytochrome c release, and ultimately cell death.
 |
INTRODUCTION |
Mitochondria generate ATP through the mitochondrial respiratory
chain (MRC),1 which is
composed of four multisubunit respiration complexes (I-IV) and two
mobile electron carriers (i.e. cytochrome c and ubiquinone). Electrons from reducing substrates such as NADH and succinate are transferred from complex I (NADH dehydrogenase) or
complex II (succinate dehydrogenase), respectively, to ubiquinone, to
complex III (cytochrome c reductase), to cytochrome
c, to complex IV (cytochrome c oxidase or COX),
and finally to O2. The electron transport through complexes
I, III, and IV is accompanied by the pumping of protons from the matrix
to the intermembrane space, where the protons establish a mitochondrial
membrane potential ( m) by forming a proton and a pH
gradient. The reverse flow of the protons from the intermembrane space
into the matrix drives another multiprotein complex,
F0F1-ATPase (or complex V), to produce ATP. The
protein subunits in complexes I, III, IV, and V are encoded by both
nuclear and mitochondrial genomes, thus necessitating smooth
communications between and coordinated gene expressions from two
genomes (1). Abnormal MRC functions due to genetic defects or chemical
disruption, for example, result in a deficiency in ATP generation,
leading to cell necrosis (2-4).
Mitochondria also play a pivotal role in regulating another mode of
cell death, i.e. apoptosis. Mitochondria generally play a
proapoptotic role in most model systems, evoking different mechanisms including ROS production (5-7), Ca2+ release (8, 9),
 m collapse (10), opening of the permeability transition
pores (PTP) (11, 12), matrix swelling and outer membrane rupture (13),
and release of apoptogenic factors including cytochrome c
(14, 15), apoptosis-inducing factor (16), second mitochondria-derived
activator of caspase (Smac/DIABLO; see Refs. 17 and 18), Smac-related
serine protease HtrA2 (19-22), endonuclease G (23), and caspases (24,
25). Exactly how these diverse mechanisms converge to activate caspases is still unclear. Two apoptotic pathways are relatively well understood at the molecular level. In the intrinsic (or mitochondrial) pathway, apoptotic signaling somehow impacts mitochondria such that the mitochondrial cytochrome c is released into the cytosol,
where it binds to the adaptor protein Apaf-1 and procaspase-9, leading to the formation of apoptosome and subsequent activation of
"executioner" caspases such as caspase-3, -6, or -7 (26). In the
extrinsic pathway, engagement of the cell surface death receptors
(e.g. Fas, TNFR1, DR-3, DR-4, and DR-5) results in the
activation of initiator caspase-8 through adaptor proteins such as FADD
and TRADD (27), which then activates downstream executioner caspases. The death receptor pathway can be amplified by the mitochondrial pathway either through the translocation of tBid, a caspase 8 cleavage
product of Bid, to the mitochondria, which induces cytochrome c release (28, 29), or through the mitochondrial release of Smac, which neutralizes the inhibitory effect of inhibitor of apoptosis
proteins on caspases (17, 18, 30).
Apoptosis induced by many stimuli seems to depend on MRC. For example,
MRC function has been reported to be required for apoptosis induced by
TNF- (31-33), lipoxygenase inhibitor nordihydroguaiaretic acid (34), butyrate, and some other short chain fatty acids (35),
ceramide (36), hydroxamic acid compound BMD188 (37), manganese (38),
synthetic retinoid CD437 (39), O2 deprivation (40),
oxidants such as tert-butylhydroperoxide (41) and hydrogen peroxide (42), and Ca2+ overloading (43). Thus, in these
apoptotic model systems, MRC-deficient 0 cells are more
resistant to apoptosis, and MRC inhibitors (such as rotenone and
antimycin A) block or inhibit apoptosis. Also in support of the
dependence of apoptosis on MRC, complex I deficiency in leukemia cells
results in apoptosis resistance (44). Deficiency in complex IV in colon
carcinoma cells renders them resistant to apoptosis induction (35).
Similarly, F0F1-ATPase is required for
Bax-induced apoptosis (45).
The molecular mechanisms underlying this MRC-dependent
apoptosis remain unclear. Here we report that apoptosis induced by BMD188, a chemical that causes cell death in an
MRC-dependent manner (37), involves an early up-regulation
of MRC proteins (in particular, cytochrome c) prior to
caspase activation and cell death. Importantly, this phenomenon seems
to represent a general early apoptotic response as it is also observed
in multiple cell types induced to die by a variety of stimuli.
 |
MATERIALS AND METHODS |
Cells and Reagents
Human osteosarcoma cells 143B(TK ) (143B) and
fibroblasts GM701.2-8C (GM701) and their respective mtDNA-less,
respiration-deficient 0 derivatives 143B206 and
GM701.2-8C (2) cells (46) were kindly provided by Dr. M. King (Thomas
Jefferson University). 143B and GM701 cells were cultured in
Dulbecco's minimum essential medium (Invitrogen) supplemented with
10% heat-inactivated fetal bovine serum (FBS) and antibiotics. 143B206
and GM701.2-8C (2) cells were cultured in Dulbecco's minimum
essential medium with high glucose supplemented with 100 µg/ml
pyruvate, 200 ng/ml ethidium bromide, 50 µg/ml uridine, 10% FBS, and
antibiotics. Human prostate cancer cells, PC3 and LNCaP, and breast
carcinoma cells, MDA-MB231, were purchased from ATCC (Manassas, VA) and
cultured in RPMI 1640 supplemented with 5 and 10% FBS, respectively.
The 0 PC3 clone 6 cells (37) were cultured as for
143B206 cells.
The primary antibodies used were listed in Table I. Secondary
antibodies, i.e. goat, donkey, or sheep anti-mouse or rabbit IgG conjugated to horseradish peroxidase, fluorescein isothiocyanate, or rhodamine, together with ECL (enhanced chemiluminescence) reagents were acquired from Amersham Biosciences. Fluorogenic caspase substrates DEVD-AFC and LEHD-AFC, pan-caspase inhibitor z-VAD-fmk, and
caspase-3/6/7 inhibitor, z-DEVD-fmk, were bought from Biomol (Plymouth
Meeting, PA). Ponasterone and Zeocin were purchased from Invitrogen.
Annexin V conjugated to AlexaFluor 568 and mitochondrial dyes were
purchased from Molecular Probes (Eugene, OR). Liposome FuGENE 6 was
bought from Roche Molecular Biochemicals. All other chemicals were
purchased from Sigma unless specified otherwise.
Subcellular Fractionation and Western Blotting
Mitochondria were prepared using differential centrifugation
(37, 47, 48) with slight modifications. Briefly, cells were treated
with various chemicals or vehicle (ethanol or Me2SO) control. In some experiments, cells were pretreated with protein synthesis inhibitor cycloheximide (CHX), RNA synthesis inhibitor actinomycin D (A/D), or mitochondrial protein synthesis inhibitor tetracycline before apoptosis induction. At the end of the treatment, cells were harvested by scraping, washed twice in ice-cold PBS, and
resuspended in 600 µl of homogenizing buffer (20 mM
HEPES-KOH, pH 7.5, 10 mM KCl, 1.5 mM
MgCl2, 1 mM sodium EDTA, 1 mM
sodium EGTA, and 1 mM dithiothreitol) containing 250 mM sucrose and a mixture of protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1% aprotinin, 1 mM leupeptin, 1 µg/ml pepstatin A, and 1 µg/ml chymostatin). After 30 min of incubation on ice, cells were homogenized in the same buffer using a glass Pyrex homogenizer (type A pestle, 140 strokes). Unbroken cells, large plasma membrane pieces, and nuclei were
removed by centrifuging the homogenates at 500 × g for
5 min at 4 °C. The resulting supernatant was centrifuged at 10,000 × g for 20 min to obtain mitochondria. The
remaining supernatant was again subjected to centrifugation at
100,000 × g for 1 h to obtain the cytosolic
fraction (i.e. S100 fraction). The mitochondrial pellet was
washed three times in homogenizing buffer, and then solubilized in TNC
buffer (10 mM Tris acetate, pH 8.0, 0.5% Nonidet P-40, 5 mM CaCl2) containing protease inhibitors.
Protein concentration was determined by Micro-BCA kit (Pierce).
For Western blotting, 25 µg of proteins (mitochondrial or cytosolic
fractions) was loaded in each lane of a 15% SDS-polyacrylamide gel.
After gel electrophoresis and protein transfer, the membrane was probed
or reprobed, after stripping, with various primary and corresponding
secondary antibodies (37, 47). Western blotting was performed using ECL
as described previously (37, 47).
Measurement of Apoptosis
Apoptosis was measured using several biochemical and biological approaches.
PARP Cleavage--
PARP cleavage assays were performed as
described previously (37, 47).
Caspase-3 Activation--
Caspase-3 cleavage (activation) was
analyzed by Western blotting. Cells were lysed in TNC lysis buffer, and
100 µg of whole cell lysates was separated on 15% SDS-PAGE. After
protein transfer, the blot was probed with a monoclonal antibody for
caspase-3. The activation of caspase-3 was monitored by a decrease or
disappearance of the ~32-kDa procaspase-3 (37).
DEVDase and LEHDase Activity--
Cells were washed twice in
PBS, and the whole cell lysates were made in the lysis buffer (50 mM HEPES, 1% Triton X-100, 0.1% CHAPS, 1 mM
dithiothreitol, and 0.1 mM EDTA). Forty µg of protein was
added to a reaction mixture containing 30 µM fluorogenic
peptide substrates, DEVD-AFC or LEHD-AFC, 50 mM of HEPES,
pH 7.4, 10% glycerol, 0.1% CHAPS, 100 mM NaCl, 1 mM EDTA, and 10 mM dithiothreitol, in a total
volume of 1 ml and incubated at 37 °C for 1 h. Production of
7-amino-4-trifluoromethylcoumarin (AFC) was monitored in a spectrofluorimeter (Hitachi F-2000 fluorescence spectrophotometer) using excitation wavelength 400 nm and emission wavelength 505 nm. The
fluorescent units were converted into nanomoles of AFC released per h
per mg of protein using a standard curve. The results were generally
presented as fold activation over the control.
DNA Fragmentation--
Fragmented DNA was extracted using
SDS/RNase/proteinase K methods (37, 47), and 20 µg of DNA was run on
1.2% agarose gel.
Quantification of Apoptotic Nuclei Using DAPI
Staining--
Cells were plated on glass coverslips (4 × 104 cells/18-mm2 coverslip) and the next day
treated with vehicle control (i.e. ethanol or
Me2SO) or various inducers. Thereafter, cells were
incubated live with DAPI (0.5 µg/ml) for 10 min at 37 °C followed
by washing. The percentage of cells exhibiting apoptotic nuclei, as
judged by chromatin condensation or nuclear fragmentation, was assessed by fluorescence microscopy (49). An average of 600-700 cells was
counted for each condition.
Immunofluorescence Analysis of Cytochrome c Distribution,
Mitochondrial Membrane Potential, and Apoptosis
Cells grown on glass coverslips were treated for various time
intervals. Fifteen min prior to the end of the treatment, cells were
incubated live with MitoTracker Orange CMTMRos to label mitochondria (37). Then cells were fixed in 4% paraformaldehyde for 10 min followed
by permeabilization in 1% Triton X-100 for 10 min. After washing in
PBS, cells were first blocked in 20% goat whole serum for 30 min at
37 °C and then incubated with monoclonal anti-cytochrome c antibody (clone 6H2.B4, 1:500) for 1 h at 37 °C.
Finally, cells were incubated with fluorescein
isothiocyanate-conjugated goat anti-mouse IgG (1:1000) for 1 h at
37 °C. After thorough washing, coverslips were mounted on slides
using Vectashield mounting medium (Vector Laboratories, Inc.,
Burlingame, CA) and observed under an Olympus BX40 epifluorescence
microscope. Images were captured with MagnaFire software and processed
in Adobe Photoshop. In a separate set of samples, following apoptotic
treatments, cells were washed once with 1× PBS and then incubated in
the Annexin-Binding Buffer containing annexin V-AlexaFluor
conjugates for 30 min followed by washing. Images were captured on an
Olympus IX50 inverted fluorescence microscope.
RT-PCR Analysis of Cytochrome c and COX II mRNA
Expression
Total RNA was isolated using Tri-Reagent (Invitrogen). RT was
performed using 2 µg of total RNA (at 42 °C for 2 h) in a
total 20-µl reaction volume containing random hexamers and
Superscript II reverse transcriptase (Invitrogen). PCR primers,
designed based on the published cytochrome c and COX
II cDNA sequences, are 5'-TTTGGATCCAATGGGTGATGTTGAG-3' (cytochrome
c, sense), 5'-TTTGAATTCCTCATTAGTAGCTTTTTTGAG-3' (cytochrome c, antisense), 5'-CCATCCCTACGCATCCTTTAC-3'; (COX II, sense),
and 5'-GTTTGCTCCACAGATTTCAGAG-3' (COX II, antisense). For PCR, 1 µl of cDNA was used in a 25-µl reaction containing 0.5 µM primers, dNTPs and Taq, using the cycling
profile 94 °C × 45 s, 56 °C × 1 min, and
72 °C × 1 min for 14 cycles for COX II and 23 cycles for
cytochrome c with a final extension at 72 °C for 10 min.
PCR products were analyzed on 1% agarose gel. RT-PCR of glyceraldehyde 3-phosphate dehydrogenase (50) was used as a control.
Transient Transfection with pEGFP-Cytochrome c
The pEGFP-cytochrome c expression plasmid, in which
the full-length rat cytochrome c cDNA was cloned into
the NheI and XhoI sites of the pEGFP-N1
(Clontech), was kindly provided by Dr. A.-L. Nieminen (Case Western Reserve University; see Ref. 51). GM701 cells,
plated 1 day earlier on 10-cm culture dishes to achieve 50-60%
confluence, were transfected, using FuGENE 6, with 15 µg of either
empty vector alone or pEGFP-cytochrome c. Twenty four h
after transfection, cells were treated with BMD188 for various times
and then harvested and used for subcellular fractionations as described
above. To assess apoptosis, GM701 cells grown on coverslips were
transfected with 1 µg of plasmids. Twenty four h later, cells were
treated with BMD188 followed by DAPI staining as described above. The
percentage of GFP-positive and -negative cells with apoptotic nuclear
morphology was determined by fluorescence microscopy (49). At least
600-700 cells were counted for each condition.
Up-regulation of Cytochrome c Using the Ecdysone-inducible
System
Plasmids pVgRXR and pIND were obtained from Invitrogen.
pIND/cyt-c-GFP was prepared by cloning the
NheI/NotI fragment of the rat cytochrome
c-GFP fusion cDNA from pEGFP-cytochrome c
(51) into pIND/V5-His-B, whereas pIND-GFP was prepared by cloning the EGFP fragment (from pEGFP-N1) between the HindIII and
NotI sites of pIND/Hygro (courtesy of Dr. T.-J. Liu, MD
Anderson Cancer Center, Houston, TX). Ecdysone-inducible cell lines
were generated in two steps. First, GM701 cells were transfected with
pVgRXR by electroporation (1025 microfarads, 260 V in a Bio-Rad
apparatus). Stable transfectants were selected with Zeocin (500 µg/ml) for 3-4 weeks and stable clones isolated using a cloning
ring. The stable clones, named EcR-GM701, were characterized by GFP
expression in response to ponasterone (2 µM) after
transient transfection with pIND-GFP. EcR-293 cells were kindly
provided by Dr. M. Bedford. In the second step, EcR-GM701 and EcR-293
cells were electroporated with pIND/cyt-c-GFP or pIND/GFP followed by
G418 (1 mg/ml) selection. Stable clones were picked by ring cloning and
screened by immunoblotting using antibody against GFP upon ponasterone
(2 µM) induction. GM701-pIND/cyt-c-GFP, GM701-pIND/GFP,
293-pIND/cyt-c-GFP, and 293-pIND/GFP cells were maintained in Zeocin
(500 µg/ml) and G418 (1 mg/ml)-containing medium. These cells were
used in subcellular fractionation and apoptosis studies upon treatment
with ponasterone for various times.
Up-regulation of Cytochrome c Using the pCMS-EGFP Expression
System
Full-length cDNA sequence of human cytochrome c
was synthesized by PCR amplification using Taq polymerase
(Eppendorf, Germany) and cloned between the EcoRI and XbaI
sites of pCMS-EGFP vector (Clontech). The Kozak
sequence was introduced in sense primer. The resultant plasmid was
sequenced and designated as pCMS-EGFP/cyt-c, in which cytochrome
c and EGFP are synthesized from two separate promoters.
GM701 fibroblasts were either untransfected or transfected with the
empty vector (pCMS-EGFP) or pCMS-EGFP/cyt-c. Twentyfour h after
transfection, cells were harvested, and mitochondrial and cytosolic
fractions were prepared, and 25 µg/lane of protein from each sample
was separated by 15% SDS-PAGE. Following protein transfer, the
membranes were probed and reprobed with antibodies against cytochrome
c, GFP, actin, or HSP60, as indicated under "Results."
Apoptosis was quantified using the DAPI staining 24 h after transfection.
Statistical Analysis
The statistical significance between experimental groups was
determined by Student's t test using the SPSS-10 software.
Differences at p < 0.05 were considered statistically significant.
 |
RESULTS |
Multiple Apoptotic Stimuli Induce an Increase of MRC Proteins Such
as COX II and Cytochrome c Early during Apoptosis Induction--
We
demonstrated previously (37) that apoptosis of epithelial cancer cells
induced by chemical BMD188 requires the MRC function. Thus,
0 PC3 (prostate cancer) cells or PC3 cells whose MRC had
been blocked by various respiration complex-specific inhibitors were
more resistant to BMD188-induced apoptosis (37). Further experiments
demonstrate that BMD188 induces apoptosis in many other cell types,
e.g. 143B osteosarcoma cells (Supplemental Material Fig. 1S)
and GM701 fibroblasts (not shown) also in an MRC-dependent
manner. To explore the molecular mechanisms of this
MRC-dependent apoptotic pathway, we purified mitochondrial
and S100 cytosolic fractions and used them in quantitative Western
blotting to examine the protein levels of two essential MRC components,
cytochrome c, which is encoded by the nuclear gene, and COX
II, which is encoded by the mitochondrial genome. The protein levels
were then correlated with caspase activation, which is measured by
DEVDase activity, caspase-3 activation, or PARP cleavage, and with
apoptosis, which is quantitated by counting apoptotic nuclei (see
details under "Materials and Methods").
By using the above approach, we found that treatment of 143B cells with
BMD188 induced a rapid (within 5 min) increase in the protein level of
COX II (Fig. 1A). COX II
protein was never detected in the cytosolic fractions in all of our
experiments (Fig. 1A and not shown), suggesting that there
was no substantial mitochondrial damage during subcellular
fractionations and that the cytosolic fractions were not contaminated
with the mitochondrial proteins. The reciprocal experiments measuring
the lactate dehydrogenase (a cytosolic protein) activity also indicated
that there was minimal contamination of the mitochondrial fractions
with the cytosolic proteins (not shown). The COX II protein level
plateaued at 30 min to 1 h after BMD188 treatment and slightly
declined thereafter (Fig. 1A). Interestingly, 15 min
post-BMD188 treatment, the total cytochrome c protein level
also increased, in both cytosol and mitochondria (Fig. 1A),
as revealed by monoclonal antibody against cytochrome c
clone 7H8.2C12, which recognizes both apocytochrome c
(i.e. cytochrome c in the cytosol without heme
attached) and holocytochrome c (i.e. cytochrome
c in the mitochondria with heme attached). (Note that,
depending on the respiration status, a small amount of cytochrome
c is often detected in the cytosol of untreated cells.) The
cytochrome c levels continued to increase until ~1 h when
an ~4-fold increase of cytochrome c was detected in both
cytosol and mitochondria, and 22% of the cells were apoptotic (Fig.
1A). When ~50% 143B cells were apoptotic and prominent
PARP cleavage (an indication of caspase activation) was observed at 2 h, cytochrome c levels in both compartments slightly
decreased (Fig. 1A). Note that PARP cleavage becomes
detectable only after sufficient numbers of cells have undergone
apoptosis (e.g. see Fig. 1, A-E). By 4 h
when most PARP was cleaved and ~90% of the cells were apoptotic,
significant amounts of mitochondrial cytochrome c similar to
the basal level and of cytosolic cytochrome c higher than
the basal level were still observed (Fig. 1A). Note that 7H8.2C12 also detected an ~50-kDa protein labeled as
X-protein, whose identity remains unclear (37, 47,
52).

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 1.
Up-regulation of MRC proteins early during
apoptosis induction. Western blot analysis of cytosolic and
mitochondrial fractions from 143B cells treated with BMD188
(A), GM701 cells treated with BMD188 (B),
MDA-MB-231 cells treated with VP16 (C), PC3 cells treated
with sodium butyrate (D), and LNCaP cells treated with serum
starvation (E). Mitochondrial and cytosolic fractions were
prepared, and 25 µg of proteins (cytosolic or mitochondrial
fractions) from each sample was used in Western blotting for cytochrome
c, COX II, and actin. Several different biochemical (PARP
cleavage, caspase-3 activation, and DEVDase activity) and biological
(i.e. apoptotic nuclear morphology upon DAPI labeling of
live cells) methods were used, in different combinations, to assess
apoptosis (see "Materials and Methods"). In some samples
(e.g. A, B, and D), the cytosol blots
were incubated with a mixture of antibodies to both cytochrome
c and actin. Data shown are representative of 3-5
independent experiments.
|
|
Similarly, treatment of GM701 fibroblasts with BMD188 rapidly
up-regulated COX II as well as cytochrome c (Fig.
1B). Increased COX II was detected at 10 min and plateaued
by 1 h after drug treatment (Fig. 1B). Increased
cytochrome c was observed in both cytosol (~3-fold) and
mitochondria (~1.5-fold) in the first 10-20 min, and by 30 min the
increase became more obvious (5-fold in cytosol and 2.5-fold in
mitochondria) (Fig. 1B). By 1 h, when ~12% cells
were apoptotic, peak levels of cytochrome c in both cytosol
(10-fold increase) and mitochondria (4-fold increase) were observed
(Fig. 1B). By 2 h when ~60% of the cells was
apoptotic and PARP was cleaved, mitochondrial cytochrome c
began to decrease, whereas the cytosolic cytochrome c level
remained about the same (Fig. 1B). By 4 h when ~90%
of cells were apoptotic and PARP was nearly completely cleaved,
cytochrome c levels in both cytosol and mitochondria
decreased (Fig. 1B). As observed previously (37) in PC3
cells, in both 143B and GM701 cells treated with BMD188, apoptosis
could be dose-dependently inhibited by z-VAD-fmk, a pan-caspase inhibitor, as well as by z-DEVD-fmk, a caspase-3/6/7 inhibitor (not shown), suggesting that the cell death is
caspase-dependent. Collectively, data presented in Fig. 1,
A and B, together with our previous observations
showing early induction of COX I (encoded by mitochondrial genome) and
COX IV (encoded by the nuclear genome) (37), suggest that there is an
early induction of MRC proteins during apoptosis induced by BMD188, an
agent whose pro-apoptotic effect depends on MRC (37).
To determine whether this early induction of MRC proteins is restricted
only to MRC-dependent apoptotic stimuli, we carried out
similar experiments in multiple cell types with a variety of apoptotic
inducers of different mechanisms of action. First, we treated MDA-MB231
breast cancer cells with VP16 (etoposide), a commonly used
chemotherapeutic drug that inhibits DNA topoisomerase II. As shown in
Fig. 1C, maximum up-regulations of COX II and cytochrome
c occurred as early as 12 h after drug treatment.
Nearly all up-regulated cytochrome c was present in the
mitochondria in MDA-MB231 cells treated with VP16 (Fig. 1C),
which is different from 143B or GM701 cells treated with BMD188 (Fig.
1, A and B). By 12 h no caspase activation
and significant death were detected (Fig. 1C). By 24 h
caspases (i.e. DEVDase) were activated ~3-fold, and
~30% of the cells were apoptotic (Fig. 1C). By 48 h
after the drug treatment when obvious caspase-3 cleavage and
DEVDase activity were detected, PARP was cleaved, and 60% of the
cells were apoptotic, maximum levels of cytochrome c and COX
II were still observed in the mitochondria (Fig. 1C). By
72 h when nearly 80% of the cells were apoptotic and prominent
caspase-3 cleavage occurred, cytochrome c in the
mitochondria decreased but the COX II protein level remained about the
same (Fig. 1C). There was a slight increase of cytochrome
c in the cytosol 24-72 h after VP16 treatment (Fig.
1C). Apoptosis in MDA-MB-231 cells was
dose-dependently inhibited by z-VAD-fmk or z-DEVD-fmk
(not shown), suggesting that the VP16-induced cell death is also
caspase-dependent.
Likewise, treatment of PC3 cells with butyrate, a short chain fatty
acid inhibitor of histone deacetylase (35), resulted in a
time-dependent up-regulation of COX II and cytochrome
c in both cytosolic and mitochondrial compartments (Fig.
1D). By 24 h post-treatment when caspase activity
increased by 13-fold, PARP was cleaved, and ~40% of the cells were
apoptotic, the maximum amount of cytochrome c accumulated in
the mitochondria (Fig. 1D). Starting from 48 h on, the
mitochondrial cytochrome c began to decrease accompanied by
an increase in the cytosolic cytochrome c (Fig.
1D). Similarly, in LNCaP cells subjected to serum
starvation, maximum induction of COX II was observed by day 2, after
which the COX II protein remained at a similar level up to day 10 (Fig. 1E and data not shown). By contrast, a
time-dependent up-regulation of cytochrome c in
the mitochondria was observed (Fig. 1E). Two days after
withdrawal of serum, increased cytochrome c in the mitochondria and maximum level of cytochrome c in the
cytosol were observed (Fig. 1E). There was slightly
increased procaspase-3 cleavage and cell death at this time point (Fig.
1E). By 4 days when further increased caspase-3 activation
and cell death were observed, the mitochondrial cytochrome c
continued to increase while the cytosolic cytochrome c
slightly decreased. By 6 days when obvious caspase-3 activation, PARP
cleavage, and apoptosis were observed, the mitochondrial cytochrome
c reached peak level, whereas the cytosolic cytochrome
c level remained unchanged (Fig. 1E). By 8 days
when caspase-3 and PARP were completely cleaved and 80% of the cells
apoptotic, the mitochondrial cytochrome c was almost
completely lost, and the cytosolic cytochrome c also decreased (Fig. 1E).
Similar studies in PC3 cells treated with camptothecin and DLD-1 (colon
cancer) cells treated with herbimycin also revealed rapid
up-regulations of cytochrome c and COX II (not shown).
Altogether, these data demonstrate that early up-regulation of MRC
proteins such as COX II and cytochrome c represents a common
early event in apoptosis induced by diverse stimuli.
Increased Cytochrome c and COX II Proteins Result from
Transcriptional Activation--
Cytochrome c is a cytosolic
protein encoded by a nuclear gene. Upon synthesis, depending on the
metabolic status of the cells, the majority or a fraction of the
apocytochrome c rapidly translocates to the mitochondria to
participate in the electron transport (1). Within mitochondria,
apocytochrome c is "anchored" to cytochrome c
heme lyase and turns into holocytochrome c upon heme binding (1, 53). Therefore, the increased cytochrome c protein
levels in both cytosol and mitochondria (Fig. 1, A-E)
suggest an increased transcription and/or translation. To test this
possibility, we used semi-quantitative RT-PCR to analyze the mRNA
levels of cytochrome c and COX II during the early phase of
apoptosis induction by some of the inducers used in Fig. 1. As shown in
Fig. 2A, treatment of GM701
cells with BMD188 resulted in a maximum increase in cytochrome c mRNA as early as 15 min, which remained elevated at
similar levels until 2 h. Similarly, maximum induction of COX II
mRNA was also observed at 15 min post-BMD188 treatment, which
decreased by 1 h (Fig. 2A). The induction of both
cytochrome c and COX II mRNAs was inhibited by A/D,
which inhibits RNA transcription. CHX, a protein synthesis inhibitor,
did not significantly affect cytochrome c mRNA level but
significantly inhibited the mRNA of mitochondria-encoded COX II
(Fig. 2A). The combination of A/D and CHX resulted in
slightly greater inhibition of the cytochrome c and COX II
mRNAs than either inhibitor alone (Fig. 2A). As
expected, CHX and A/D, either individually or in combination, inhibited BMD188 up-regulated COX II and cytochrome c proteins in
GM701 cells (not shown). Similar RT-PCR analysis was carried out in MDA-MB231 cells treated with VP16. As shown in Fig. 2B, the
cytochrome c mRNA was maximally induced as early as 30 min post-treatment, which stayed up-regulated at similar levels up to
4 h, the longest time interval examined. In contrast, COX II
mRNA was up-regulated in a time-dependent manner, and
the peak-level induction was observed at 4 h (Fig. 2B).
CHX significantly inhibited both cytochrome c and COX II
mRNA expression, and A/D demonstrated a more prominent inhibitory
effect (Fig. 2B), which is different from BMD188-treated GM701 cells. The combination of CHX and A/D inhibited their mRNA up-regulations more significantly than either treatment alone (Fig.
2B). Together, these results suggest that the up-regulated COX II and cytochrome c proteins early during apoptosis
induction (Fig. 1, B and C) resulted from an
increased mRNA transcription. That CHX also inhibited the mRNA
expression of COX II and/or cytochrome c (Fig. 2,
A and B) is probably due to inhibition of the
transcriptional machinery by CHX.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 2.
Transcriptional activation of cytochrome
c and COX II genes and inhibition of apoptosis by
transcription and translation inhibitors. A and
B, transcriptional up-regulation of cytochrome c
(Cyt-c) and COX II. A, GM701 fibroblast cells
were treated with BMD188 (40 µM); or B,
MDA-MB-231 cells were treated with VP16 (10 µM) for the
time intervals indicated. Some samples were pretreated with
cycloheximide (CHX, 1 µM), actinomycin D (A/D, 1 nM), or both for 1 h before apoptotic stimulation.
RT-PCR was performed as detailed under "Materials and Methods."
Data are representative of at least five separate experiments.
C and D, inhibition of apoptosis by protein
and RNA synthesis inhibitors. GM701 (C) or MDA-MB-231
(D) cells grown on glass coverslips were treated with BMD188
(40 µM, 2 h) or VP16 (10 µM, 48 h), respectively, either alone or in the presence of CHX, A/D, or both
as indicated. The percentages of apoptotic cells upon DAPI staining
were enumerated under a fluorescent microscope. Values represent the
mean ± S.D. from five separate experiments. *, p < 0.05; **, p < 0.01 (Student t test)
compared with cells treated BMD188 (C) or VP16
(D) alone.
|
|
To assess the potential importance of de novo RNA and/or
protein synthesis in the above apoptotic models, GM701 (Fig.
2C) and MDA-MB-231 (Fig. 2D) cells were
pretreated with A/D, CHX, or both 1 h before treating with BMD188
and VP16, respectively. The results indicate that pretreatment of cells
with these inhibitors significantly inhibited apoptosis, and the
inhibition was more pronounced in VP16-treated MDA-MB231 cells. In both
cases, the combination of A/D and CHX resulted in greater inhibition of
apoptosis than either inhibitor alone (Fig. 2, C and
D).
Cytochrome c Up-regulation in Relation to Cytochrome c Release and
Caspase Activation--
The preceding experiments demonstrate that
multiple apoptotic stimuli, perhaps through transcriptional activation,
up-regulate cytochrome c, leading to increased cytochrome
c protein levels in both mitochondria and cytosol. In the
intrinsic apoptotic pathway, mitochondrial holocytochrome c
is released into the cytosol to trigger caspase activation, and only
the holo- but not apocytochrome c has the apoptogenic effect
(14). The anti-cytochrome c antibody (i.e.
7H8.2C12) utilized in the experiments of Fig. 1 recognizes both apo-
and holocytochrome c (Table
I). Consequently, we could not determine
whether the increased cytochrome c in the cytosol (Fig. 1,
A-E) represents the newly synthesized apocytochrome
c, mitochondrially released holocytochrome c, or
a mixture of both. R & D Systems has recently developed an antibody
that specifically recognizes holocytochrome c (Table I). We
thus took advantage of this antibody and utilized BMD188 as the primary
apoptotic inducer to address the relationships among cytochrome
c up-regulation, cytochrome c release, and
caspase activation.
In untreated GM701 cells holocytochrome c existed only in
the mitochondria (Fig. 3A).
Fifteen min post-BMD188 treatment, slightly increased holocytochrome
c was observed in the mitochondria, but no holocytochrome
c could be detected in the cytosol (not shown). By 30 min,
there was a substantial increase in the mitochondrial holocytochrome
c accompanied by a small amount of holocytochrome c release into the cytosol. By 1 h, the mitochondrial
holocytochrome c level remained about the same as at 30 min,
but the holocytochrome c level in the cytosol dramatically
increased (Fig. 3A). By 2 h, the majority of
holocytochrome c was released from the mitochondria, whereas
the holocytochrome c level in the cytosol remain about the
same as at 1 h (Fig. 3A). By 4 h, the
holocytochrome c in both mitochondria and cytosol could
hardly be detected. These changes in holocytochrome c were
confirmed by fluorescence microscopy (see Fig.
4). Combined with the data presented in
Fig. 1B and 2A, the following scenario can be
presented to explain the cytochrome c movement. Early
(i.e. within 10-15 min) post-BMD188 treatment, cytochrome
c is transcriptionally up-regulated resulting in increased cytochrome c protein, part of which is transported into the
mitochondria and part of which is retained in the cytosol. By 30 min,
continued cytochrome c up-regulation leads to further
increased holocytochrome c enrichment in the mitochondria
and, at the same time, a low level of mitochondrial holocytochrome
c begins to be released. By 1 h, the total cytochrome
c level (as detected by 7H8.2C12) reaches a maximum in the
mitochondria (Fig. 1B), whereas the holocytochrome c level in the mitochondria remains about the same as at 30 min (Fig. 3A), suggesting that at this time point either
significant cytochrome c release is taking place or
mitochondria are no longer able to convert apocytochrome c
to holocytochrome c. The high level of holocytochrome
c in the cytosol at 1 h (Fig. 3A) supports the former possibility. By 2 h, 7H8.2C12 still detects a high level of cytochrome c in the mitochondria (Fig.
1B), but the mitochondrial holocytochrome c is
nearly completely released into the cytosol (Fig. 3A; also
see Fig. 4I), suggesting that mitochondria can no longer
convert the newly synthesized and transported apocytochrome c to holocytochrome c at this time point. By
4 h, 7H8.2C12 still detects a significant amount of cytochrome
c in both mitochondria and cytosol (Fig. 1B), but
the holocytochrome c in both compartments is barely
detectable (Fig. 3A), suggesting that most of the cytochrome c detected by 7H8.2C12 at this time point is apocytochrome
c. The nearly complete disappearance of holocytochrome
c in both mitochondria and cytosol probably results from
either its preferential release outside of the cells (54) or
preferential degradation.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 3.
Cytochrome c alterations in
relation to caspase activation (A-C), changes in
Bcl-2 family proteins (D), and release of
mitochondrial proteins larger than cytochrome c
(E). A, GM701 cells were treated with
BMD188, and mitochondrial (Mito) and cytosolic fractions
were prepared as described under "Materials and Methods." Forty
µg of cytosolic or mitochondrial proteins from each sample was used
in Western blotting for holocytochrome c together with
actin. B and C, whole cell lysates (40 µg) were
used to measure LEHDase activity (B) and DEVDase activity
(C), respectively. D and E, the same
blot as shown in A was stripped and sequentially reprobed
for various Bcl-2 family proteins (D) or for Smac and HSP60
(E). Note that essentially identical results were obtained
for Bak and Bax when using antibodies that recognize the
conformationally active proteins (Table I; data not shown). Data shown
are representative of 3-5 independent experiments.
|
|

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 4.
Loss of
 m precedes cytochrome
c release during BMD188-induced GM701 cell
apoptosis. Shown are representative microphotographs of cytochrome
c (A, C, E, G,
and I) and MitoTracker labeling of mitochondria
(B, D, F, H, and
J) in GM701 cells treated with BMD188 (40 µM)
for 0 (A and B), 15 (C and
D), and 30 min (E and F), and 1 (G and H), and 2 h (I and
J). Another set of experiments with identical time points
was performed to identify apoptotic cells using annexin V (see
Supplemental Material Fig. 2S). See text for detailed discussions.
Consistent with the Western blotting data and our previous observations
(37), increased cytochrome c labeling was observed between
15 min and 1 h under the microscope, which was not well reproduced
on micrographs. Original magnifications. ×200.
|
|
Next, we correlated cytochrome c alterations with the
activation of the initiator caspase, caspase-9, and the executioner caspase, caspase-3. As shown in Fig. 3, B and C,
caspase-9 (i.e. LEHDase activity) and caspase-3
(i.e. DEVDase activity) activation was observed at 1 h
and reached the maximum levels by 2 h. In all apoptotic systems
examined (Fig. 1 and data not shown), caspase activation (as judged by
procaspase cleavage and/or substrate cleavage) was observed concomitant
with or downstream of cytochrome c release.
Together, these results (Fig. 1, Fig. 2, A and B,
and Fig. 3, A-C) suggest early cytochrome c
up-regulation and translocation to the mitochondria preceding
holocytochrome c release and caspase activation in
BMD188-induced apoptosis of GM701 fibroblasts. Similarly, VP16-treated
MDA-MB231 cells showed up-regulated cytochrome c mRNA as
early as 30 min (Fig. 2B) and maximally induced cytochrome c protein, most of which accumulated in the mitochondria by
12 h (Fig. 1C). However, cytochrome c
release from the mitochondria (not shown), caspase activation, and cell
death (Fig. 1C) were not observed until ~24 h, again
suggesting early cytochrome c up-regulation and
translocation to the mitochondria preceding cell death. Similar
sequence of alterations was also observed in serum-starved LNCaP
cells.2
Cytochrome c Release Involves Dynamic Changes in Bcl-2 Family
Proteins, Loss of  m, and Opening of PTP--
Next, we
carried out four sets of experiments in BMD188-treated GM701 cells to
investigate the potential mechanisms of cytochrome c
release. In the first, we examined the involvement of Bcl-2 family
proteins as they play an essential role in regulating mitochondrial integrity and cytochrome c release (26, 55). Specifically, we examined three BH3-only proteins (i.e. Bim, Bad, and
Bid), two multidomain proapoptotic proteins (i.e. Bax and
Bak), and two multidomain anti-apoptotic proteins (i.e.
Bcl-2 and Bcl-xL). As shown in Fig. 3D, dynamic
changes were observed with these proteins. Bim, detected only in the
mitochondria, was up-regulated (Fig. 3D), resulting from
transcriptional activation (not shown). Bad, detected mainly in the
cytosol, showed a time-dependent translocation to the
mitochondria until 2 h, when the mitochondria-associated Bad could
hardly be detected. By 4 h, the mitochondria-associated Bad was
undetectable, and the cytosolic Bad was mostly gone (Fig. 3D). Bid cleavage and activation, evidenced by the
appearance of tBid in the mitochondria, was observed at 2 h and
completed at 4 h (Fig. 3D), suggesting that this is a
relatively late event, consistent with caspase-8 cleavage and
activation starting from 2 h (not shown). Bax, detected equally in
cytosol and mitochondria, showed somewhat complex alterations. Between
30 min and 2 h, Bax in both compartments was decreased. By 4 h, however, the cytosolic Bax was significantly decreased with a
concomitant increase in the mitochondria (Fig. 3D). Bak,
detected only in the mitochondria, on the other hand, showed a
time-dependent increase that plateaued at 1 h (Fig.
3D). Interestingly, antibodies recognizing conformationally active Bax and Bak (Table I) revealed essentially identical changes in
the two proteins (not shown). Bcl-2 and Bcl-xL showed very similar changes; both proteins showed a time-dependent
increase exclusively in the mitochondria (Fig. 3D). The
early increase in the mitochondrial Bcl-xL may also involve
its translocation from the cytosol as a decreased cytosolic
Bcl-xL protein level was observed at 30 min post-treatment
(Fig. 3D). These data suggest that dynamic changes in the
Bcl-2 family proteins may be involved in cytochrome c
release in BMD188-induced GM701 cell death.
In the second set of experiments, we examined the release of two other
mitochondrial proteins that are significantly larger than cytochrome
c: Smac, an ~25-kDa intermembrane protein (17, 18), and
HSP60, a 60-kDa heat-shock protein localized in the matrix (56). As
shown in Fig. 3E, Smac release, similar to holocytochrome c release (Fig. 3A), was observed 30 min after
BMD188 treatment and plateaued by 2 h. Also similar to cytochrome
c, the mitochondrial Smac protein level demonstrated a
steady increase (Fig. 3E), suggesting an up-regulated
transcription and/or translation. Interestingly, significant amounts of
Smac still existed at 2 and 4 h when the majority of
holocytochrome c had been released into the cytosol (compare
Fig. 3, E and A), perhaps reflecting continuously
up-regulated Smac synthesis just as significant amounts of cytochrome
c in the mitochondria detected by 7H8.2C12 at these time
points (see Fig. 1B). In contrast to holocytochrome
c and Smac, HSP60 was maximally released as early as 30 min,
and its levels in the mitochondria and cytosol remained relatively
constant after 30 min until 4 h (Fig. 3E). Together,
these data suggest that proteins significantly bigger than cytochrome
c are also released during BMD188-induced apoptosis of GM701 cells.
In the third set of experiments, we used immunofluorescence microscopy
and 6H2.B4, an antibody that recognizes only holocytochrome c in immunostaining (Table I), to examine the relationship
between  m and mitochondrial cytochrome c
release. As shown in Fig. 4A, holocytochrome c in
untreated GM701 fibroblasts was distributed in the mitochondria, which
colocalized with MitoTracker labeling (Fig. 4B). No
significant changes were observed in the staining patterns of
cytochrome c and mitochondria by 15 min (Fig. 4,
C and D). By 30 min, most cytochrome c
was clearly localized in the mitochondria (Fig. 4E),
consistent with only very low levels of holocytochrome c
release detected on Western blotting (see Fig. 3A). However,
most mitochondria had lost the  m as indicated by the loss
of MitoTracker labeling (Fig. 4F). Interestingly, nuclei
were labeled by the MitoTracker dye starting from 30 min (compare Fig.
3F with B and D). Labeling with
AlexaFluor-annexin V revealed similar degrees of low basal level
apoptosis before and at 30 min (see Supplemental Material Fig. 2S,
A-F). Consistent with Western blotting data (Fig.
3A), cytochrome c release became prominent by
1 h (Fig. 4G), when all mitochondria had lost the  m (Fig. 4H). Meanwhile, apoptosis
significantly increased (Supplemental Material Fig. 2S,
G-H). By 2 h, cytochrome c was completely
released from mitochondria (Fig. 4I), fully consistent with
the Western blotting data (Fig. 3A). MitoTracker labeling was barely detectable (Fig. 4J), and apoptosis became
widespread (Supplemental Material Fig. 2S, I and
J). By 4 h neither cytochrome c nor
MitoTracker labeling could be seen (not shown). These fluorescence microscopy results provide direct confirmation of the Western blotting
data and also indicate that loss of  m precedes holocytochrome c release from mitochondria. Similar changes
in  m and holocytochrome c release were also
observed in MDA-MB-231 cells treated with VP16 (not shown).
Loss of  m may result from opening of PTP, which in turn
may be involved in cytochrome c release (10-12). To test this possibility, in the final set of experiments, we pretreated GM701
cells with cyclosporin A (CsA), which directly inhibits PTP (10-12),
and NAC which indirectly inhibits PTP by blocking ROS generation (11,
12, 34), before apoptotic stimulation with BMD188. As shown in Fig.
5, both CsA and NAC partially inhibited holocytochrome c release, caspase activation, and apoptosis
in GM701 cells.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 5.
Inhibitors of PTP and ROS generation inhibits
cytochrome c release, caspase activation, and
apoptosis in GM701 cells treated with BMD188. Cells were
pretreated with CsA (5 µM) or NAC (1 µM)
for 1 h, followed by addition of BMD188 (40 µM) for
2 h. Cytosolic fractions were prepared as described under
"Materials and Methods," and 40 µg of proteins was used in
Western blotting for holocytochrome c together with actin.
The percentage of apoptotic cells was determined under a fluorescent
microscope upon DAPI staining. DEVDase activity was measured using 40 µg of whole cell lysates. Data shown are representative of at least
three independent experiments.
|
|
Increased Transport of Cytosolic Cytochrome c into the Mitochondria
Is Independent of MRC--
The preceding experiments demonstrate that
apoptosis induced by multiple stimuli is preceded by an up-regulation
of cytochrome c synthesis and transport into the
mitochondria. Normal cytochrome c transport into the
mitochondria has been shown to be mediated by a unique mechanism that
does not depend on mitochondrial respiration or  m (1,
53). To determine whether or not the continuously enhanced cytochrome
c transport into the mitochondria during apoptosis depends
on MRC or  m, we employed two experimental strategies. In
the first, we pretreated PC3 cells with tetracycline, which inhibits
the mitochondrial protein synthesis and the MRC activity (1), prior to
BMD188 treatment. As shown in Fig.
6A, inhibition of MRC function
by tetracycline significantly delayed caspase activation, consistent
with the previous observations (37) that BMD188-induced PC3 cell
apoptosis requires MRC. Treatment with tetracycline also resulted
in, as expected, the retention of most cytochrome c in the
cytosol (Fig. 6B, 0 lane), because the protein is
not needed for the electron transport (1). Upon BMD188 treatment, a
time-dependent translocation of cytosolic cytochrome
c to mitochondria was still observed (Fig. 6B),
suggesting that the BMD188-induced increase of cytochrome c
transport to the mitochondria does not depend on MRC per
se.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 6.
BMD188-induced PC3 cell apoptosis, but not
BMD188-stimulated cytochrome c translocation to the
mitochondria, depends on MRC. A, tetracycline inhibits
BMD188-induced caspase activation in PC3 cells. PC3 cells were
pretreated with tetracycline (1 µg/ml) for 1 h and then treated
with BMD188 (40 µM) in the presence of tetracycline.
Whole cell lysates were prepared at the time points indicated and used
to measure DEVDase activity. B, MRC-inhibited PC3 cells
treated with tetracycline still show a time-dependent
translocation of cytochrome c from cytosol to the
mitochondria upon BMD188 treatment. Thirty µg/lane of the
fractionated cytosolic or mitochondrial proteins (see "Materials and
Methods") was used in Western blotting for cytochrome c.
C, respiration-deficient 0 PC3 (clone 6)
cells (37) still show cytochrome c translocation to the
mitochondria in response to BMD188 treatment. Thirty µg/lane of the
fractionated cytosolic or mitochondrial proteins was used in Western
blotting for cytochrome c. In the meantime, 0
PC3 cells treated with BMD188 for the same time intervals were also
used to measure DEVDase activity and apoptosis.
|
|
In the second strategy, we treated MRC-deficient 0 PC3
cells (clone 6) (37) with BMD188. As in tetracycline-pretreated PC3 cells, the majority of cytochrome c in untreated
0 PC3 cells was retained in the cytosol (Fig.
6C, 0 lane). BMD188 treatment again induced a
rapid translocation of cytosolic cytochrome c to the
mitochondria (Fig. 6C). The accumulation of cytochrome c in the mitochondria reached peak level at ~4 h after
BMD188 treatment, at which time increased caspase activation and
apoptosis were observed (Fig. 6C). In wild-type,
respiration-competent PC3 cells, 40 µM BMD188 induced
maximum caspase activation and killed ~90% of the cells within
4 h (37). In contrast, BMD188 at the same dose induced similar
levels of caspase activation and apoptosis in 0 PC3
cells only after ~24 h treatment (Fig. 6C). Together with the tetracycline experiments, these observations suggest that the
BMD188-induced cell death but not cytochrome c translocation to the mitochondria depends on the MRC function.
Up-regulation of Cytochrome c Alone Is Insufficient to Induce
Apoptosis but Potentiates Cell Death by BMD188--
To test whether
increased cytochrome c synthesis and enrichment in the
mitochondria contribute to apoptosis induction, we transiently
transfected GM701 cells with an expression plasmid encoding cytochrome
c-GFP (cyt-c-GFP) fusion protein, which has been shown
previously (51) to localize effectively to the mitochondria and to be
released from the mitochondria during staurosporine-induced apoptosis. Twenty-four h after transfection, cells were treated with
BMD188 for various lengths of time, followed by quantification of
apoptotic nuclei in both GFP-positive as well as GFP-negative cells. As
shown in Fig. 7A, GM701 cells
transfected with the GFP alone (control vector) showed similar levels
of apoptosis in both GFP+ and GFP
populations. In contrast, in GM701 cells transfected with the cyt-c-GFP, the BMD188-induced apoptosis was significantly enhanced (Fig. 7A). For example, 3 h after BMD188 treatment,
>90% of the GFP+ cells was apoptotic compared with
~60% of apoptosis in GFP cells (Fig.
7A).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 7.
Overexpression of cytochrome c
enhanced BMD188 induced apoptosis (A) but cytochrome
c overexpression by itself (i.e. without
stimulation) is insufficient to trigger apoptosis (B).
A, GM701 fibroblast cells were transfected with plasmids
encoding GFP or cyt-c-GFP. Twenty four h later, cells were treated with
BMD188 (30 µM) for the times indicated. Cells were
labeled live with DAPI 15 min before the end of the treatment followed
by fixation in 4% paraformaldehyde. Apoptosis was quantified by
nuclear morphology. The results are presented as % of apoptosis
in both GFP+ or GFP cell populations. Values
represent the mean ± S.D. from three separate experiments. *,
significantly different (p < 0.01, Student's
t test) compared with GFP cells. B
and C, Western blot analysis of cytosolic and mitochondrial
fractions from GM701-pIND/cyt-c-GFP (B) and
293-pIND/cyt-c-GFP (C) cells induced by ponasterone (2 µM) for the time intervals indicated. Twenty five
µg/lane of proteins from each sample was separated by 15% SDS-PAGE.
Following protein transfer, membranes were probed and reprobed with
antibodies against COX II, cytochrome c (which recognizes
only endogenous cytochrome c but not cyt-c-GFP), or GFP
(which recognizes GFP or cyt-c-GFP). Apoptosis and DEVDase activity
were determined as described under "Materials and Methods." Data
presented are representative of three separate experiments.
|
|
The above results suggest that up-regulation of cytochrome c
by enforced expression potentiated apoptosis induced by BMD188. To
address whether up-regulation of cytochrome c is by itself sufficient to induce apoptosis, we used an ecdysone-inducible system to
establish transcriptionally inducible cytochrome c in GM701
and 293 cells. Double stable clones of each cell type expressing inducible GFP or cyt-c-GFP in response to a ligand such as ponasterone were generated in two steps as detailed under "Materials and
Methods." The resultant cells, i.e. GM701-pIND/GFP,
GM701-pIND/cyt-c-GFP, 293-pIND/GFP, and 293-pIND/cyt-c-GFP cells, were
treated with 2 µM ponasterone for various time intervals
to induce the expression of GFP or cyt-c-GFP. As shown in Fig. 7,
B and C, ponasterone induced a rapid induction of
cyt-c-GFP, the majority of which, like endogenous cytochrome
c, was localized in the mitochondria, whereas
ponasterone-induced GFP alone was mainly localized in the cytosol (not
shown). Ponasterone treatment did not affect the expression of
endogenous cytochrome c or COX II (Fig. 7, B and
C). Up-regulation of cyt-c-GFP in both GM701 (Fig.
7B) and 293 (Fig. 7C) cells did not lead to
increased caspase activation or apoptosis.
In the above experiments, we utilized the cyt-c-GFP fusion protein,
which, although being able to correctly target to the mitochondria (see
Ref. 51; data not shown), might not be fully functional as an electron
carrier in the MRC because of the presence of the GFP tag. To exclude
this possibility, we made a new expression construct, pCMS-EGFP/cyt-c,
in which the human cytochrome c (without any tag) and the
EGFP are independently synthesized from two separate promoters (see
"Materials and Methods"). In this way, cytochrome c
and GFP are made as two separate proteins. By using this vector, we
carried out experiments similar to those in Fig. 7, B and
C. As shown in Supplemental Material Fig. 3S, as early as
24 h after transient transfection of pCMS-EGFP/cyt-c, the
cytochrome c level was significantly up-regulated
(~4-fold) only in the mitochondria, compared with untransfected cells
or cells transfected with the empty vector. As expected, GFP was
detected only in the cytosol of the transfected cells (Fig. 3S).
Because the up-regulated cytochrome c was detected only in
the mitochondria, it is reasonable to think that this exogenous
cytochrome c, just like the endogenous protein, should be
functional in participating in MRC electron relays. Nevertheless, there
was no significantly increased cell death at 24 (Fig. 3S) to 72 h
(not shown) after the transfection. Together, this set of experiments
provides independent supporting evidence that up-regulation of
cytochrome c alone is insufficient in inducing apoptosis.
 |
DISCUSSION |
Up-regulation of MRC Proteins and Mitochondrial Activation Early
during Apoptosis Induction--
Our previous studies (37) and the
present work show that apoptosis induced by multiple stimuli is
temporally preceded by an early induction of MRC proteins such
as cytochrome c and COX II. For example, induction of
cytochrome c and COX II mRNAs and proteins in GM701
cells treated with BMD188 occurs within 10 min (Fig. 1B and
2A), preceding caspase activation and death, which becomes
detectable at 30 min to 1 h (Figs. 1B and 3;
Supplemental Material Fig. 2S). Similarly, up-regulated cytochrome
c and COX II mRNAs and proteins in MDA-MB231 cells
treated with VP16 occur much earlier than caspase activation and
apoptosis (Figs. 1C and 2). Recent work by others has also
revealed increased expressions of cytochrome c and COX II
preceding cell death in Jurkat cells treated with camptothecin (57) or
breast cancer cells treated with teniposide (58). The increased
cytochrome c and COX II proteins in these apoptotic model
systems appear to result from the transcriptional activation of the
respective genes, as illustrated in BMD188-treated GM701 cells (Fig.
2A) and VP16-treated MDA-MB231 cells (Fig. 2B).
Because COX II is encoded by the mitochondrial genome and cytochrome
c the nuclear genome, these observations suggest that the
MRC components encoded by both genomes are coordinately induced early
in apoptotic signal transduction by these stimuli. In support, two
other MRC proteins, COX I and COX IV, also encoded by the mitochondrial
and nuclear genomes, respectively (1), are similarly up-regulated
during apoptosis induced by BMD188 (37), camptothecin (57), and
teniposide (58).
Why should cells up-regulate these MRC proteins in response to
apoptotic stimuli of diverse mechanisms of action (see Refs. 37, 57,
and 58; this study)? Multiple pieces of evidence suggest that the
up-regulation of MRC proteins may represent one aspect of a more global
mitochondrial activation response (Fig. 8). First, not only MRC proteins but also
many mitochondrially localized, non-MRC proteins are up-regulated. For
example, in BMD188-induced GM701 cell death, Bcl-2 family proteins Bim,
Bak, and Bcl-2 as well as Smac, all encoded by the nuclear genes and normally localized exclusively in the mitochondria, are up-regulated (Fig. 3, D and E). Similarly, both Bim and Bcl-2
are also induced in serum-starved LNCaP cells and VP16-treated
MDA-MB231 cells.2 Second, apoptosis induced by many of
these apoptotic stimuli exemplified by BMD188 (37), camptothecin (57),
staurosporine (13), Fas (59), and Mn(II) (38) is preceded by an
early hyperpolarization of the  m (Fig. 8), thus
indicative of enhanced electron transport and MRC activity. Third,
these inducers rapidly up-regulate the oxygen consumption capacity of the cells (e.g. 37, 57, 58) or COX activity (35), suggesting that the up-regulated MRC components are functionally participating in
the electron transport. Finally, mitochondria represent the primary
site of ROS generation in the cells, and enhanced MRC activity is
generally accompanied by increased ROS production (5-7). Indeed,
increased ROS generation has been observed early in apoptosis induced
by most of these stimuli including TNF- , Fas, BMD188,
nordihydroguaiaretic acid, camptothecin, Fas, Mn(II), retinoid
CD437, ceramide, short chain fatty acids, hypoxia, and deprivation
(31-43, 57-59). Altogether, these observations suggest that one of
the common events in apoptosis induced by a wide spectrum of stimuli is
early mitochondrial activation manifested as increased synthesis of
mitochondrially localized (both MRC and non-MRC) proteins and increased
 m, oxygen consumption, and ROS production (Fig. 8).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 8.
A scheme illustrating the sequence of events
in MADAP, highlighting the potentially critical role of early
mitochondrial activation in causing subsequent mitochondrial
dysfunction and cytochrome c release.
|
|
This early mitochondrial activation could represent a defensive
response of cells to various stresses. However, the fact that cells
lacking a functional MRC (i.e. 0 cells) or
cells with deficient MRC function due to either chemical blocking or
genetic mutation/deletion of individual respiratory proteins are often
resistant to apoptosis induction (31-43) (Supplemental Material Fig.
1S; see discussion in Introduction) strongly suggests that the MRC and
early mitochondrial activation are also causally involved in apoptosis
induction (see below). In this sense, apoptosis triggered by the
stimuli that cause early mitochondrial activation and require the
mitochondrial activation for the apoptotic effect can be called
mitochondrial activation-dependent
apoptotic pathway or MADAP.
Importance of Early Mitochondrial Activation and Cytochrome c
Up-regulation in MADAP--
How might early mitochondrial activation
contribute to apoptosis induction? We shall address this question later
in the context of cytochrome c release. However, a detailed
look at the potential role of cytochrome c movement in
BMD188-induced GM701 cell death may shed some light on this question.
Early upon stimulation the apoptotic signals rapidly up-regulate
cytochrome c, some of which translocates to the
mitochondria. As the increased cytochrome c synthesis in the
cytosol and transport into the mitochondria continue and intensify,
holocytochrome c is gradually released from the mitochondria
into the cytosol to initiate apoptosome formation. Remarkably,
increased cytochrome c synthesis and transport are still
observed even when holocytochrome c is nearly completely released from the mitochondria (Figs. 1B, 2A, and
3A). Therefore, cytochrome c undergoes cyclic
changes in this apoptotic model, i.e. increased
apocytochrome c synthesis in the cytosol increased apocytochrome c transport into the mitochondria increased holocytochrome c accumulation in the mitochondria
increased holocytochrome c release into the cytosol the whole cycle continues until all holocytochrome c is
released from the mitochondria and until mitochondria no longer have
the ability to convert up-regulated apocytochrome c to
holocytochrome c.
Several pieces of evidence suggest that the increased cytochrome
c translocation to and its accumulation in the mitochondria might contribute to apoptosis induction. First, in all the cases studied, the translocation of cytochrome c to and its
accumulation in the mitochondria occur prior to caspase activation and
cell death (Fig. 1, A-E and data not shown). Second, in
0 and tetracycline-treated PC3 cells, although
cytochrome c translocation still occurs, its peak
accumulation in the mitochondria is delayed, i.e. from ~1
to 2-4 h (37) (Fig. 6, B and C of this work). In the meantime, caspase activation as well as cell death are also delayed
(Fig. 6; 37). Third, inhibition of de novo mRNA
synthesis by A/D or protein synthesis by CHX inhibits BMD188 and
VP16-induced up-regulation in COX II and cytochrome c as
well as apoptosis (Fig. 2). Although A/D and CHX may likely affect many
other gene and protein targets, it is reasonable to think that their
inhibitory effects on cytochrome c up-regulation, at least
partially, contribute to their inhibition of apoptosis. Finally,
enforced overexpression of exogenous cytochrome c, which
also rapidly translocates to the mitochondria (not shown),
significantly potentiates apoptosis (Fig. 7A).
Interestingly, simply up-regulating cytochrome c expression is insufficient to trigger apoptosis; in the absence of an apoptotic inducer, up-regulated cytochrome c does not increase
spontaneous cell death (Fig. 7, B and C;
Supplemental Material Fig. 3S). These observations suggest that the
accumulation of cytochrome c in the mitochondria may
represent only one of the apoptosis-initiating factors and that it is
the combination of many factors during mitochondrial activation that
eventually leads to mitochondrial dysfunction, cytochrome c
release, and caspase activation (see below).
How is the newly synthesized cytochrome c transported into
the mitochondria during MADAP? Normally, most cytochrome c,
upon synthesis, is immediately transported to the mitochondria in which the protein turns into holocytochrome c as the result of
binding to the heme group, and this transport process utilizes a unique import pathway that does not depend on the MRC or  m (1,
53). Likewise, the increased transport of cytochrome c to
the mitochondria in BMD188-induced PC3 cell death does not depend on
the MRC or  m, as it also occurs in 0 cells
or when MRC is inhibited by tetracycline (Fig. 6). In support of this
conclusion, increased cytochrome c accumulation in the mitochondria is still observed long after the mitochondria have lost
the  m (compare Figs. 1B, 3A, and
4).
Our observation that cytochrome c can be transcriptionally
up-regulated leading to increased apocytochrome c proteins
in the cytosol has a practical implication. In the literature,
frequently only the increased cytosolic cytochrome c levels
are shown, and this is used as evidence of cytochrome c
release from the mitochondria. Without using an antibody that
specifically recognizes the holocytochrome c (Table I) and
without demonstrating correspondingly decreased mitochondrial
cytochrome c, however, it will be unable to distinguish whether the increased cytochrome c in the cytosol results
from mitochondrial release or from the transcriptional up-regulation of
the gene.
How Might Cytochrome c Be Released during MADAP?--
The
apoptogenic holocytochrome c is normally sequestered in the
mitochondrial intermembrane space. The outer mitochondrial membrane
(OMM) has a limited permeability allowing the passage of molecules
<1.5 kDa, and the inner mitochondrial membrane (IMM) is essentially
impermeable. Although still highly debatable, three major models have
been proposed to explain how cytochrome c might be released
from the mitochondria during apoptosis (60). In the first, proapoptotic
Bcl-2 family proteins, Bax and Bak in particular, directly form pores
on OMM to release selectively cytochrome c without major
effects on mitochondrial function (61-63). In the second model,
apoptotic signals open the PTP resulting in the loss of  m
and swelling of the mitochondrial matrix, which causes eventual OMM
rupture, nonselective OMM permeabilization, and cytochrome c
release (63-65). In the third model, apoptotic signaling evokes the
opening of a voltage-independent megapore termed MAC (mitochondria
apoptosis-induced channel) (66). MAC is distinct from PTP in that it
does not have voltage-dependent anion channel (VDAC,
located in OMM) as a component, and it displays multiple conductance
levels, with a peak single channel opening of ~2.5 nS, corresponding
to a pore diameter of ~4.5 nm (66). Therefore, MAC is significantly
bigger than the Bax/Bak channel or PTP (66).
None of these models alone seems to be able to explain completely how
cytochrome c might be released during MADAP. Instead, dynamic changes in Bcl-2 family proteins, opening of PTP and loss of
 m, and opening of much larger pores (that can allow the
release of HSP60 from the matrix) all seem to be involved. For example,
in BMD188-induced GM701 cell death, all three BH3 domain-only proteins,
i.e. Bim, Bad, and Bid, are activated; Bim is up-regulated
transcriptionally (Fig. 3D and data not shown); Bad rapidly
translocates to the mitochondria, and Bid is cleaved late during
apoptosis (Fig. 3D). In contrast, the multidomain Bcl-2
proteins show complex alterations; both Bcl-xL and Bcl-2 are induced and concentrated in the mitochondria, and Bak is induced whereas Bax is reduced early during apoptosis induction (Fig. 3D). Similar alterations such as rapid induction of Bim
mRNA and protein have also been observed in MDA-MB231 cells treated
with VP16 and LNCaP cells subjected to serum starvation.2
Because the Bcl-2 proteins normally function in the mitochondria to
maintain the organelle integrity and functional homeostasis (26, 55,
63, 64, 67), these dynamic changes may reflect the life-and-death
"battle" among these proteins. Thus, it is possible that, as Bim
and Bad are activated and Bak is induced, Bax is down-regulated, and
prosurvival Bcl-2 and Bcl-xL are up-regulated in order to
prolong the cell survival. As apoptotic stimulation continues, more Bim
and Bak are induced, and more Bad is translocated to the mitochondria,
tilting the balance toward cell death. In this scenario, cytochrome
c might be released through the Bax/Bak channel (as a
significant amount of Bax is always present in the mitochondria) or
through Bak alone, which has been shown recently (68) to play a
critical role in mediating cytochrome c release in
anticancer drug-induced apoptosis.
The Bax/Bak pores are small (0.5 nS; 66) and are thought to release
selectively cytochrome c without significantly affecting mitochondrial parameters such as membrane permeability and matrix volume (61-63). In apoptosis induced by BMD188 (37) and many other
stimuli (e.g. see Refs. 13, 38, 57, and 59), there is an
early IMM hyperpolarization and increased  m followed by
subsequent loss of  m. Furthermore, at least in the case
of BMD188-induced GM701 cell death, proteins much larger than
cytochrome c (i.e. 25-kDa Smac and 60-kDa HSP60)
are also released from mitochondria. Together, these observations
suggest that cytochrome c release in these apoptotic systems
may involve opening of PTP or MAC or some other pores in addition to
Bcl-2 family proteins (Fig. 8). The supporting evidence comes from the loss of the  m at 30 min when the majority of cytochrome c in most cells is still in the organelle (Fig. 4),
suggesting PTP opening prior to cytochrome c release. More
importantly, BMD188-induced cytochrome c release and
subsequent caspase activation and cell death in GM701 cells can be
inhibited by CsA, which inhibits cyclophilin D, an important component
of the PTP, as well as by NAC, which indirectly inhibits PTP (11, 12).
The inhibitory effect of NAC also suggests ROS production by BMD188, as
observed previously (37). It is interesting to note that the patterns
of cytochrome c release and Smac are very similar (Fig. 3,
A and D), suggesting that these two intermembrane
proteins may utilize the same (or similar) channel or pore for their
exodus. Surprisingly and intriguingly, the matrix protein HSP60 is
maximally released into the cytosol much earlier, at a time when
cytochrome c/Smac release has just started (see Fig. 3,
A and D). These differential release kinetics suggest the following: 1) the release of these individual proteins is
specific, which cannot be accounted for by nonspecific rupture of OMM;
and 2) different channels or pores are probably utilized to release
different proteins.
It is noteworthy that Bim is rapidly and commonly induced in the three
MADAP systems we examined in detail, i.e. BMD188-treated GM701 cells (this study), serum-deprived LNCaP cells,2 and
VP16-treated MDA-MB231
cells,3 suggesting that this
may be the key BH3-only molecule in initiating MADAP. Interestingly,
Bim has been shown recently to induce both Bax/Bak-dependent and Bax/Bak-independent cytochrome
c release (69). In the latter mechanism, Bim directly
interacts with VDAC and triggers VDAC-dependent cytochrome
c release (69). Because VDAC is an integral component of PTP
and also forms pores with Bax (63-65), which in turn seems to be part
of the MAC (66), it is possible that all these proteins together form
very dynamic pores/channels of different sizes and selectivity at the
contact sites of IMM and OMM, which are opened by BH3-only proteins
such as Bim and closed by anti-apoptotic proteins such as Bcl-2 and Bcl-xL.
In summary, our data presented herein, together with other data
(31-45, 57, 58) suggest the apoptotic model presented in Fig. 8. In
response to a wide diversity of apoptotic stimuli, cells immediately
wage a defensive response characterized by mitochondrial activation,
manifested by rapid up-regulations of multiple MRC proteins and
enhanced MRC activities such as oxygen consumption. In the meantime,
Bcl-2 proteins undergo dynamic alterations in attempt to keep the cells
alive. In the persistent apoptotic stimulation, the increasing ROS
production as a result of continuously increased MRC activation and
cytochrome c accumulation in the mitochondria results in the
opening of PTP and/or other pores and loss of  m, which,
together with more pro-apoptotic changes in the Bcl-2 family proteins,
leads to the release of holocytochrome c and, subsequently, activation of caspases.
 |
ACKNOWLEDGEMENTS |
We thank Dr. A.-L. Nieminen for providing
pEGFP-cytochrome c; Dr. T.-J. Liu for pIND-GFP; Dr. M. Bedford for EcR-293 cells; Dr. M. King for 143B, 143B206, and
GM701.2-8C cells; Dr. A. Porter at Biomide Corp., for BMD188; Drs. K. Kiguchi and K. Klaypool for help in fluorescence microscopy; T. Higgins and Y. Yonekawa for technical assistance; and members of the
Tang laboratory for helpful discussions. We are also grateful to Dr. X. Wang for antibodies against Smac and tBid.
 |
FOOTNOTES |
*
This work was supported in part by the National Institutes
of Health NCI Grant CA 90297 and NIEHS Center Grant ES07784, and the
University of Texas MD Anderson Cancer Center institutional grants.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The on-line version of this article (available at
http://www.jbc.org) contains Figs.
1S 3S.
Supported by a Department of Defense Postdoctoral Traineeship
Award DAMD17-02-1-0083.
§
To whom correspondence should be addressed: Dept. of
Carcinogenesis, University of Texas M. D. Anderson Cancer Center,
Science Park Research Division, Park Rd. 1C, Smithville, TX 78957. Tel.: 512-237-9575; Fax: 512-237-2475; E-mail:
dtang@sprd1.mdacc.tmc.edu.
Published, JBC Papers in Press, October 28, 2002, DOI 10.1074/jbc.M207622200
2
J.-W. Liu, D. Chandra, and D. G. Tang,
manuscript in preparation.
3
D. Chandra, J.-W. Liu, and D. G. Tang,
unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
MRC, mitochondrial
respiratory chain;
A/D, actinomycin D;
AFC, 7-amino-4-trifluoromethylcoumarin;
BMD188, a hydroxamic acid compound;
CHX, cycloheximide;
COX II, cytochrome c oxidase subunit II;
CsA, cyclosporin A;
DAPI, 4',6-diamidino-2-phenylindole;
GFP, green
fluorescence protein;
MADAP, mitochondrial
activation-dependent apoptotic pathway;
PARP, poly(ADP-ribose) polymerase;
PTP, permeability transition pore;
ROS, reactive oxygen species;
RT, reverse transcriptase;
VDAC, voltage-dependent anion channel;
VP16, etoposide;
0 cells, respiration-deficient cells;
TNF- , tumor
necrosis factor- ;
AFC, 7-amino-4-trifluoromethylcoumarin;
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid;
z, benzyloxycarbonyl;
fmk, fluoromethyl ketone;
FBS, fetal bovine
serum;
PBS, phosphate-buffered saline;
EGFP, enhanced green fluorescent
protein;
IMM, inner mitochondrial membrane;
OMM, outer mitochondrial
membrane;
MAC, mitochondria apoptosis-induced channel;
NAC, N-acetylcysteine.
 |
REFERENCES |
| 1.
|
Poyton, R. O.,
and McEwen, J. E.
(1996)
Annu. Rev. Biochem.
65,
563-607[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Eguchi, Y.,
Shimizu, S.,
and Tsujimoto, Y.
(1997)
Cancer Res.
57,
1835-1840[Abstract/Free Full Text]
|
| 3.
|
Leist, M.,
Single, B.,
Castoldi, A. F.,
Kuhnle, S.,
and Nicotera, P.
(1997)
J. Exp. Med.
185,
1481-1486[Abstract/Free Full Text]
|
| 4.
|
Formigli, L.,
Papucci, L.,
Tani, A.,
Schiavone, N.,
Tempestini, A.,
Orlandini, G. E.,
Capaccioli, S.,
and Orlandini, S. Z.
(2000)
J. Cell. Physiol.
182,
41-49[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Lotem, J.,
Peled-Kamar, M.,
Groner, Y.,
and Sachs, L.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
9166-9171[Abstract/Free Full Text]
|
| 6.
|
Um, H.-D.,
Orensteine, J. M.,
and Wahl, S. M.
(1996)
J. Immunol.
156,
3469-3477[Abstract]
|
| 7.
|
Tan, S.,
Sagara, Y.,
Liu, Y.,
Maher, P.,
and Schubert, D.
(1998)
J. Cell Biol.
141,
1423-1432[Abstract/Free Full Text]
|
| 8.
|
Richter, C.
(1993)
FEBS Lett.
325,
104-107[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Gunter, T. E.,
Gunter, K. K.,
Sheu, S. S.,
and Gavin, C. E.
(1994)
Am. J. Physiol.
267,
C313-C339[Medline]
[Order article via Infotrieve]
|
| 10.
|
Zamzami, N.,
Marchetti, P.,
Castedo, M.,
Zanin, C.,
Vayssiere, J.-L.,
Petit, P. X.,
and Kroemer, G.
(1995)
J. Exp. Med.
181,
1661-1672[Abstract/Free Full Text]
|
| 11.
|
Zarotti, M.,
and Szabo, I.
(1995)
Biochim. Biophys. Acta
1241,
139-179[Medline]
[Order article via Infotrieve]
|
| 12.
|
Marzo, I.,
Brenner, C.,
Zamzami, N.,
Susin, S. A.,
Beutner, G.,
Brdiczka, D.,
Remy, R.,
Xie, Z.-H.,
Reed, J. C.,
and Kroemer, G.
(1998)
J. Exp. Med.
187,
1261-1271[Abstract/Free Full Text]
|
| 13.
|
Vander-Heiden, M. G.,
Chandel, N. S.,
Williamson, E. K.,
Schumacker, P. T.,
and Thompson, C. B.
(1997)
Cell
91,
627-637[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Liu, X.,
Kim, C. N.,
Yang, J.,
Jemmerson, R.,
and Wang, X.
(1996)
Cell
86,
147-157[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Kluck, R. M.,
Martin, S. J.,
Hoffman, B. M.,
Zhou, J. S.,
Green, D. R.,
and Newmeyer, D. D.
(1997)
EMBO J.
16,
4639-4649[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Susin, S. A.,
Lorenzo, H. K.,
Zamzami, N.,
Marzo, I.,
Snow, B. E.,
Brothers, G. M.,
Mangion, J.,
Jacotot, E.,
Costantini, P.,
Loeffler, M.,
Larochette, N.,
Goodlett, D. R.,
Aebersold, R.,
Siderovski, D. P.,
Penninger, J. M.,
and Kroemer, G.
(1999)
Nature
397,
441-446[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Du, C.,
Fang, M., Li, Y., Li, L.,
and Wang, X.
(2000)
Cell
102,
33-42[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Verhagen, A. M.,
Ekert, P. G.,
Pakusch, M.,
Silke, J.,
Connolly, L. M.,
Reid, G. E.,
Moritz, R. L.,
Simpson, R. J.,
and Vaux, D. L.
(2000)
Cell
102,
43-53[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Suzuki, Y.,
Imai, Y.,
Nakayama, H.,
Takahashi, K.,
Takio, K.,
and Takahashi, R.
(2001)
Mol. Cell
8,
613-621[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Verhagen, A. M.,
Silke, J.,
Ekert, P. G.,
Pakusch, M.,
Kaufmann, H.,
Connolly, L. M.,
Day, C. L.,
Tikoo, A.,
Burke, R.,
Wrobel, C.,
Moritz, R. L.,
Simpson, R. J.,
and Vaux, D. L.
(2002)
J. Biol. Chem.
277,
445-454[Abstract/Free Full Text]
|
| 21.
|
Hegde, R.,
Srinivasula, S. M.,
Zhang, Z.,
Wassell, R.,
Mukattash, R.,
Cilenti, L.,
DuBois, G.,
Lazebnik, Y.,
Zervos, A. S.,
Fernandes-Alnemri, T.,
and Alnemri, T.
(2002)
J. Biol. Chem.
277,
432-438[Abstract/Free Full Text]
|
| 22.
|
Martins, L. M.,
Iaccarino, I.,
Tenev, T.,
Gschmeissner, S.,
Totty, N. F.,
Lemoine, N. R.,
Savopoulos, J.,
Gray, C. W.,
Creasy, C L.,.,
Dingwall, C.,
and Downward, J.
(2002)
J. Biol. Chem.
277,
439-444[Abstract/Free Full Text]
|
| 23.
|
Li, L. Y.,
Luo, X.,
and Wang, X.
(2001)
Nature
412,
95-99[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Mancini, M.,
Nicholson, D. W.,
Roy, S.,
Thornberry, N. A.,
Peterson, E. P.,
Casciola-Rosen, L. A.,
and Rosen, A.
(1998)
J. Cell Biol.
140,
1485-1495[Abstract/Free Full Text]
|
| 25.
|
Susin, S. A.,
Lorenzo, H. K.,
Zamzami, N.,
Marzo, I.,
Brenner, C.,
Larochette, N.,
Prevost, M. C.,
Alzari, P. M.,
and Kroemer, G.
(1998)
J. Exp. Med.
189,
381-394
|
| 26.
|
Wang, X.
(2001)
Genes Dev.
15,
2922-2933[Free Full Text]
|
| 27.
|
Ashkenazi, A.,
and Dixit, V. M.
(1998)
Science
281,
1305-1308[Abstract/Free Full Text]
|
| 28.
|
Li, H.,
Zhu, H., Xu, C.-J.,
and Yuan, J.
(1998)
Cell
94,
491-501[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Luo, X.,
Budihardjo, I.,
Zou, H.,
Slaughter, C.,
and Wang, X.
(1998)
Cell
94,
481-490[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Deng, Y.,
Lin, Y.,
and Wu, X.
(2002)
Genes Dev.
16,
33-45[Abstract/Free Full Text]
|
| 31.
|
Schultze-Osthoff, K.,
Beyaert, R.,
Vandevoorde, V.,
Haegeman, G.,
and Fiers, W.
(1993)
EMBO J.
12,
3095-3104[Medline]
[Order article via Infotrieve]
|
| 32.
|
Higuchi, M.,
Aggarwal, B. B.,
and Yeh, E. T. H.
(1997)
J. Clin. Invest.
99,
1751-1758[Medline]
[Order article via Infotrieve]
|
| 33.
|
Deshpande, S. S.,
AngKeow, P.,
Huang, J.,
Ozaki, M.,
and Iran, K.
(2000)
FASEB J.
14,
1705-1714[Abstract/Free Full Text]
|
| 34.
|
Tang, D. G.,
and Honn, K. V.
(1997)
J. Cell. Physiol.
172,
155-170[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Heerdt, B. G.,
Houston, M. A.,
and Augenlicht, L. H.
(1997)
Cell Growth Differ.
8,
523-532[Abstract]
|
| 36.
|
Quillet-Mary, A.,
Jaffrezou, J.-P.,
Mansat, V.,
Bordier, C.,
Naval, J.,
and Laurent, G.
(1997)
J. Biol. Chem.
272,
21388-21395[Abstract/Free Full Text]
|
| 37.
|
Joshi, B., Li, L.,
Taffe, B. G.,
Zhu, Z.,
Wahl, S.,
Tian, H.,
Ben-Josef, E.,
Taylor, J. D.,
Porter, A. T.,
and Tang, D. G.
(1999)
Cancer Res.
59,
4343-4355[Abstract/Free Full Text]
|
| 38.
|
Oubrahim, H.,
Stadtman, E. R.,
and Chock, P. B.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
9505-9510[Abstract/Free Full Text]
|
| 39.
|
Hail, N. Jr.,
Youssef, E. M.,
and Lotan, R.
(2001)
Cancer Res.
61,
6698-6702[Abstract/Free Full Text]
|
| 40.
|
McClintock, D. S.,
Santore, M. T.,
Lee, V. Y.,
Brunelle, J.,
Budinger, G. R.,
Zong, W. X.,
Thompson, C. B.,
Hay, N.,
and Chandel, N. S.
(2002)
Mol. Cell. Biol.
22,
94-104[Abstract/Free Full Text]
|
| 41.
|
Sestili, P.,
Brambilla, L.,
and Cantoni, O.
(1999)
FEBS Lett.
457,
139-143[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Dumont, A.,
Hehner, S. P.,
Hofmann, T. G.,
Ueffing, M.,
Droge, W.,
and Schmitz, M. L.
(1999)
Oncogene
18,
747-757[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Chauvin, C., De,
Oliveira, F.,
Ronot, X.,
Mousseau, M.,
Leverve, X.,
and Fontaine, E.
(2001)
J. Biol. Chem.
276,
41394-41398[Abstract/Free Full Text]
|
| 44.
|
Kataoka, A.,
Kubota, M.,
Watanabe, K.,
Sawada, M.,
Koishi, S.,
Lin, W. W.,
Usami, I.,
Akiyama, V.,
Kitoh, T.,
and Furusho, K.
(1997)
Cancer Res.
57,
5243-5245[Abstract/Free Full Text]
|
| 45.
|
Matsuyama, S., Xu, Q.,
Velours, J.,
and Reed, J. C.
(1998)
Mol. Cell
1,
327-336[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
King, M. P.,
and Attardi, G.
(1989)
Science
246,
500-503[Abstract/Free Full Text]
|
| 47.
|
Tang, D. G., Li, L.,
Zhu, Z.,
and Joshi, B.
(1998)
Biochem. Biophys. Res. Commun.
242,
380-384[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Liu, J.-W.,
Chandra, D.,
Tang, S.-H.,
Chopra, D.,
and Tang, D. G.
(2002)
Cancer Res.
62,
2976-2981[Abstract/Free Full Text]
|
| 49.
|
Tang, D. G., Li, L.,
Chopra, D. P.,
and Porter, A. T.
(1998)
Cancer Res.
58,
3466-3479[Abstract/Free Full Text]
|
| 50.
|
Tang, D. G.,
Tokumoto, Y. M.,
and Raff, M. C.
(2000)
J. Cell Biol.
148,
971-984[Abstract/Free Full Text]
|
| 51.
|
Heiskanen, K. M.,
Bhat, M. B.,
Wang, H.W., Ma, J.,
and Nieminen, A.-L.
(1999)
J. Biol. Chem.
274,
5654-5658[Abstract/Free Full Text]
|
| 52.
|
Yang, J.,
Liu, X.,
Bhalla, K.,
Kim, C. N.,
Ibrado, A. M.,
Cai, J.,
Peng, T.-I.,
Jones, D. P.,
and Wang, X.
(1997)
Science
275,
1129-1132[Abstract/Free Full Text]
|
| 53.
|
Stuart, R. A.,
and Neupert, W.
(1990)
Biochimie (Paris)
72,
115-121
|
| 54.
|
Jemmerson, R.,
LaPlante, B.,
and Treeful, A.
(2002)
Cell Death Differ.
9,
538-548[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Ranger, A. M.,
Malynn, B. A.,
and Korsmeyer, S. J.
(2001)
Nat. Genet.
28,
113-118[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Xanthoudakis, S.,
Roy, S.,
Rasper, D.,
Hennessey, T.,
Aubin, Y.,
Cassady, R.,
Tawa, P.,
Ruel, R.,
Rosen, A.,
and Nicholson, D. W.
(1999)
EMBO J.
18,
2049-2056[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Sanchez-Alcazar, J.,
Ault, J. G.,
Khodjakov, A.,
and Schneider, E.
(2000)
Cell Death Differ.
7,
1090-1100[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Sanchez-Alcazar, J.,
Khodjakov, A.,
and Schneider, E.
(2001)
Cancer Res.
61,
1038-1044[Abstract/Free Full Text]
|
| 59.
|
Banki, K.,
Hutter, E.,
Gonchoroff, N. J.,
and Perl, A.
(2000)
J. Immunol.
162,
1466-1479
|
| 60.
|
Degterev, A.,
Boyce, M.,
and Yuan, J.
(2001)
J. Cell Biol.
155,
695-697[Abstract/Free Full Text]
|
| 61.
|
Wei, M. C.,
Zong, W. X.,
Cheng, E. H.,
Lindsten, T.,
Panoutsakopoulou, V.,
Ross, A. J.,
Roth, K. A.,
MacGregor, G. R.,
Thompson, C. B.,
and Korsmeyer, S. J.
(2001)
Science
292,
727-730[Abstract/Free Full Text]
|
| 62.
|
Waterhouse, N. J.,
Goldstein, J. C.,
von Ahsen, O.,
Schuler, M.,
Newmeyer, D. D.,
and Green, D. R.
(2001)
J. Cell Biol.
153,
319-328[Abstract/Free Full Text]
|
| 63.
|
Harris, M. H.,
and Thompson, C. B.
(2000)
Cell Death Differ.
7,
1182-1191[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
Zamzami, N.,
and Kroemer, G.
(2001)
Nat. Rev. Mol. Cell. Biol.
2,
67-71[CrossRef][Medline]
[Order article via Infotrieve]
|
| 65.
|
Shimizu, S.,
Ide, T.,
Yanagida, T.,
and Tsujimoto, Y.
(2000)
J. Biol. Chem.
275,
12321-12325[Abstract/Free Full Text]
|
| 66.
|
Pavlov, E. V.,
Priault, M.,
Pierkiewicz, D.,
Cheng, E. H.-Y.,
Antonsson, B.,
Manon, S.,
Korsmeyer, S. J.,
Mannella, C. A.,
and Kinnally, K. W.
(2001)
J. Cell Biol.
155,
719-724[Abstract/Free Full Text]
|
| 67.
|
Cheng, E. H.,
Wei, M. C.,
Weiler, S.,
Flavell, R. A.,
Mak, T. W.,
Lindsten, T.,
and Korsmeyer, S. J.
(2001)
Mol. Cell
8,
705-711[CrossRef][Medline]
[Order article via Infotrieve]
|
| 68.
|
Wang, G.-Q.,
Gastman, B. R.,
Wieckoski, E.,
Goldstein, L. A.,
Gambotto, A.,
Kim, T.-H.,
Fang, B.,
Rabinovitz, A.,
Yin, X.-M.,
and Rabinowich, H.
(2001)
J. Biol. Chem.
276,
34307-34317[Abstract/Free Full Text]
|
| 69.
|
Sugiyama, T.,
Shimizu, S.,
Matsuoka, Y.,
Yoneda, Y.,
and Tsujimoto, Y.
(2002)
Oncogene
21,
4944-4956[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. UEDA, S. INOUE, Y. ZHANG, T. KUTSUNA, S. INOUE, K. NOTO, N. ARAI, and M. NOGUCHI
Heparin Induces Apoptosis through Suppression of AKt in Oral Squamous Cell Carcinoma Cells
Anticancer Res,
April 1, 2009;
29(4):
1079 - 1088.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Chandra, G. Choy, and D. G. Tang
Cytosolic Accumulation of HSP60 during Apoptosis with or without Apparent Mitochondrial Release: EVIDENCE THAT ITS PRO-APOPTOTIC OR PRO-SURVIVAL FUNCTIONS INVOLVE DIFFERENTIAL INTERACTIONS WITH CASPASE-3
J. Biol. Chem.,
October 26, 2007;
282(43):
31289 - 31301.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T.-Y. Lee, K.-L. Tsai, W.-S. Lee, and C. Hsu
The molecular events occur during MK-801-induced cytochrome oxidase subunit II down-regulation in GT1-7 cells
J. Mol. Endocrinol.,
July 1, 2007;
39(1):
53 - 66.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Okomo-Adhiambo, C. Beattie, and A. Rink
cDNA Microarray Analysis of Host-Pathogen Interactions in a Porcine In Vitro Model for Toxoplasma gondii Infection
Infect. Immun.,
July 1, 2006;
74(7):
4254 - 4265.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Lotan, A. Rotem, H. Gonen, J. P. M. Finberg, S. Kemeny, H. Steller, A. Ciechanover, and S. Larisch
Regulation of the Proapoptotic ARTS Protein by Ubiquitin-mediated Degradation
J. Biol. Chem.,
July 8, 2005;
280(27):
25802 - 25810.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Tehranchi, R. Invernizzi, A. Grandien, B. Zhivotovsky, B. Fadeel, A.-M. Forsblom, E. Travaglino, J. Samuelsson, R. Hast, L. Nilsson, et al.
Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes
Blood,
July 1, 2005;
106(1):
247 - 253.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhang, C.-H. Cho, L.-o. Atchaneeyasakul, T. McFarland, B. Appukuttan, and J. T. Stout
Activation of the Mitochondrial Apoptotic Pathway in a Rat Model of Central Retinal Artery Occlusion
Invest. Ophthalmol. Vis. Sci.,
June 1, 2005;
46(6):
2133 - 2139.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Chandra, G. Choy, P. T. Daniel, and D. G. Tang
Bax-dependent Regulation of Bak by Voltage-dependent Anion Channel 2
J. Biol. Chem.,
May 13, 2005;
280(19):
19051 - 19061.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kondo, H. Nagano, H. Wada, B. Damdinsuren, H. Yamamoto, N. Hiraoka, H. Eguchi, A. Miyamoto, T. Yamamoto, H. Ota, et al.
Combination of IFN-{alpha} and 5-Fluorouracil Induces Apoptosis through IFN-{alpha}/{beta} Receptor in Human Hepatocellular Carcinoma Cells
Clin. Cancer Res.,
February 1, 2005;
11(3):
1277 - 1286.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.L. Taylor, S.L. Weng, P. Fox, E.H. Duran, M.S. Morshedi, S. Oehninger, and S.J. Beebe
Somatic cell apoptosis markers and pathways in human ejaculated sperm: potential utility as indicators of sperm quality
Mol. Hum. Reprod.,
November 1, 2004;
10(11):
825 - 834.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Chandra, G. Choy, X. Deng, B. Bhatia, P. Daniel, and D. G. Tang
Association of Active Caspase 8 with the Mitochondrial Membrane during Apoptosis: Potential Roles in Cleaving BAP31 and Caspase 3 and Mediating Mitochondrion-Endoplasmic Reticulum Cross Talk in Etoposide-Induced Cell Death
Mol. Cell. Biol.,
August 1, 2004;
24(15):
6592 - 6607.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kitajka, A. J. Sinclair, R. S. Weisinger, H. S. Weisinger, M. Mathai, A. P. Jayasooriya, J. E. Halver, and L. G. Puskas
Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression
PNAS,
July 27, 2004;
101(30):
10931 - 10936.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. C. Bartholomay, W.-L. Cho, T. A. Rocheleau, J. P. Boyle, E. T. Beck, J. F. Fuchs, P. Liss, M. Rusch, K. M. Butler, R. C.-C. Wu, et al.
Description of the Transcriptomes of Immune Response-Activated Hemocytes from the Mosquito Vectors Aedes aegypti and Armigeres subalbatus
Infect. Immun.,
July 1, 2004;
72(7):
4114 - 4126.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Wu, A. Owlia, and P. Singh
Precursor peptide progastrin1-80 reduces apoptosis of intestinal epithelial cells and upregulates cytochrome c oxidase Vb levels and synthesis of ATP
Am J Physiol Gastrointest Liver Physiol,
December 1, 2003;
285(6):
G1097 - G1110.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Gybina and J. R. Prohaska
Increased Rat Brain Cytochrome C Correlates with Degree of Perinatal Copper Deficiency Rather than Apoptosis
J. Nutr.,
November 1, 2003;
133(11):
3361 - 3368.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Bhatia, C. J. Maldonado, S. Tang, D. Chandra, R. D. Klein, D. Chopra, S. B. Shappell, P. Yang, R. A. Newman, and D. G. Tang
Subcellular Localization and Tumor-suppressive Functions of 15-Lipoxygenase 2 (15-LOX2) and Its Splice Variants
J. Biol. Chem.,
June 27, 2003;
278(27):
25091 - 25100.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Chandra and D. G. Tang
Mitochondrially Localized Active Caspase-9 and Caspase-3 Result Mostly from Translocation from the Cytosol and Partly from Caspase-mediated Activation in the Organelle. LACK OF EVIDENCE FOR Apaf-1-MEDIATED PROCASPASE-9 ACTIVATION IN THE MITOCHONDRIA
J. Biol. Chem.,
May 2, 2003;
278(19):
17408 - 17420.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|